BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20972710)

  • 1. [Current aspects of breast carcinoma: 2].
    Petru E
    Wien Med Wochenschr; 2010 Nov; 160(19-20):477. PubMed ID: 20972710
    [No Abstract]   [Full Text] [Related]  

  • 2. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
    Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating the genetic make-up of breast cancer: a new fashion?
    Linn SC; Jonkers J
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1065-7. PubMed ID: 17725409
    [No Abstract]   [Full Text] [Related]  

  • 5. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
    Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
    Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side.
    Garber JE; Golshan M
    J Clin Oncol; 2009 Dec; 27(35):5862-4. PubMed ID: 19858367
    [No Abstract]   [Full Text] [Related]  

  • 7. [Genetic testing in patients at risk for carcinoma of the breast].
    Kiechle M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
    [No Abstract]   [Full Text] [Related]  

  • 8. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The case against BRCA 1 and 2 testing.
    Lin C; Sasaki T; Strumwasser A; Harken A
    Surgery; 2011 Jun; 149(6):731-4. PubMed ID: 21621683
    [No Abstract]   [Full Text] [Related]  

  • 10. BRCA screening.
    Med Lett Drugs Ther; 2007 Nov; 49(1274):93-4. PubMed ID: 18007543
    [No Abstract]   [Full Text] [Related]  

  • 11. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
    J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
    Meyer P; Voigtlaender T; Bartram CR; Klaes R
    Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1/2-associated and sporadic breast cancers: fellow travelers or not?
    Garber JE
    Cancer Prev Res (Phila); 2009 Feb; 2(2):100-3. PubMed ID: 19174575
    [No Abstract]   [Full Text] [Related]  

  • 16. More on breast cancer guidelines.
    Nassar BA; Ludman MD; Costa MT; Welch JP; Butts CA; Love JR; Hogg H; Beis MJ
    CMAJ; 1998 Jun; 158(11):1429; author reply 1429-30. PubMed ID: 9629100
    [No Abstract]   [Full Text] [Related]  

  • 17. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
    Ahn SH; Son BH; Yoon KS; Noh DY; Han W; Kim SW; Lee ES; Park HL; Hong YJ; Choi JJ; Moon SY; Kim MJ; Kim KH; Kwak BS; Cho DY
    Cancer Lett; 2007 Jan; 245(1-2):90-5. PubMed ID: 16455195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
    Yurgelun MB; Hiller E; Garber JE
    J Clin Oncol; 2015 Oct; 33(28):3092-5. PubMed ID: 26282646
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 20. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
    Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
    Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.